Glyburide vs Glucovance in the Treatment of GDM (GGIG)
Glyburide vs Glucovance in the Treatment of Gestational Diabetes
Sponsor: Texas Tech University Health Sciences Center, El Paso
Terminated
Lack of Recruitment
Other terminated trials from Texas Tech University Health Sciences Center, El Paso
- COVID-19 Pneumonia · Phase PHASE3 · May 2024
- Cerebral Cavernous Malformation · Aug 2023
- Septic Arthritis · Phase NA · Apr 2022
- Solid Tumor · Phase NA · Oct 2020
- Adenomyosis · Dec 2017
See all terminations from Texas Tech University Health Sciences Center, El Paso
Other Gestational Diabetes trials with similar outcome
This EARLY_PHASE1 trial investigates Gestational Diabetes and is currently terminated or withdrawn. Texas Tech University Health Sciences Center, El Paso leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Dec 2018 — Nov 2020 [monthly]
Terminated NA
Status: Recruiting → Terminated
▶ Show 2 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Texas Tech University Health Sciences Center, El Paso
For direct contact, visit the study record on ClinicalTrials.gov .